Company News
Suven Life Sciences Reaches 76% Masupirdine Phase 3 Enrollment
Suven Life Sciences announced 76% enrollment completion in its 375-patient global Phase 3 trial for Masupirdine treating Alzheimer's agitation.
The company targets Last Patient In by September 2026 an
